Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Psychiatry indexChapter sections
Purpose and principlesIndications, selection and cautionsAssessment before treatmentTreatment approachRegimens, contraindications and interactionsComplications, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook10 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Lithium initiation, monitoring and toxicity

Psychiatry · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Suspected lithium toxicity

New vomiting or diarrhoea, coarse tremor, ataxia, dysarthria, confusion, marked drowsiness, muscle weakness, seizure or arrhythmia in a lithium-treated person is toxic until urgently assessed, even if a recent level was therapeutic.

Action: Withhold lithium, assess ABCDE and hydration and obtain an urgent plasma lithium concentration, urea, electrolytes, creatinine, eGFR, calcium, glucose and ECG as clinically indicated. Arrange emergency medical and toxicology assessment; treat complications and do not restart until the cause and safe regimen are established.

Purpose and principles

Initiate lithium only with complete baseline and shared-care safeguards, interpret correctly timed plasma levels, prevent interaction and dehydration-related harm, and act on clinical toxicity without waiting for a numerical threshold.

Lithium is effective but has a narrow therapeutic index and is eliminated predominantly through the kidneys. Safe treatment depends on the relationship between dose, formulation, sampling time, renal function, fluid and sodium balance and interacting medicines. A number without this context is easily misinterpreted. Confirm the exact product and schedule, because bioavailability differs between preparations and changing brand should be managed like re-initiation with renewed level checks.

Complete the initiation sequence before the first prescription. Discuss expected benefit, delayed preventive effect, common adverse effects, toxicity and the consequences of missed doses or rapid discontinuation. Record weight or BMI, full blood count, urea and electrolytes including calcium, eGFR and thyroid function. Offer ECG when cardiovascular disease or risk factors are present and assess pregnancy or plans. Provide written safety information and monitoring record and establish who prescribes, orders, reviews and acts on results.

Indications, selection and cautions

Expected early effects

Fine tremor, thirst, polyuria, nausea or mild cognitive dulling may occur but still require review of burden, level and alternatives.

Neurotoxicity pattern

Coarse tremor, ataxia, dysarthria, confusion, marked drowsiness or neuromuscular change is concerning regardless of the last recorded concentration.

Volume-depletion trigger

Gastrointestinal loss, fever, low intake or heavy sweating reduces renal lithium clearance and can turn a stable regimen toxic.

Interaction-triggered rise

NSAIDs, renin-angiotensin system inhibitors and diuretics can reduce lithium clearance, particularly after initiation or dose change.

End-organ burden

Declining eGFR, thyroid dysfunction, hypercalcaemia, weight change, polyuria or cardiac symptoms require trend-based benefit and harm reassessment.

Red flags requiring action

  • Coarse tremor, unsteady gait, dysarthria, confusion, reduced consciousness, seizure or new neuromuscular signs suggests clinically significant neurotoxicity.
  • Vomiting, diarrhoea, fever, profuse sweating, poor fluid intake or acute kidney injury can rapidly raise lithium exposure and requires sick-day assessment.
  • A newly prescribed NSAID, ACE inhibitor, angiotensin receptor blocker or diuretic can increase lithium concentration and needs immediate interaction review and extra monitoring.

Assessment before treatment

  1. 01
    Required pre-treatment baselineFirst step
    Why
    Measure weight or BMI, FBC, renal function, electrolytes, calcium and thyroid function before exposure.
    Interpretation and limitations
    Correct abnormalities and seek specialist advice where organ impairment changes safety; baseline values allow later trends to be recognised.
  2. 02
    Indicated ECG and pregnancy assessment
    Why
    Identify cardiovascular conduction risk and reproductive circumstances that alter the treatment decision.
    Interpretation and limitations
    An ECG is required when cardiovascular disease or risk is present; pregnancy requires individual specialist planning, not unsupervised abrupt cessation.
  3. 03
    Correctly timed plasma lithium level
    Why
    Guide individual dose after initiation, change, suspected non-adherence, relapse, interaction or toxicity.
    Interpretation and limitations
    Record product, last dose and sample time. Interpret the value with symptoms and renal-fluid context; a therapeutic result cannot exclude toxicity.
  4. 04
    Six-month organ surveillance
    Why
    Trend eGFR, urea and electrolytes, calcium, thyroid function and weight or BMI during maintenance.
    Interpretation and limitations
    Serial eGFR fall or biochemical change prompts more frequent monitoring and joint renal-psychiatric review rather than a single automatic stop threshold.

Treatment approach

01Initiation sequenceBaseline, consent and shared care firstFirst stepLithium is selected for an adult who has not previously taken it or is restarting after a clinically significant interruption.+
  1. 1Discuss benefits, adverse effects, toxicity, interactions, pregnancy, adherence and discontinuation and confirm the person can use monitoring and safety information.
  2. 2Complete weight or BMI, FBC, renal-electrolyte-calcium and thyroid tests, plus indicated ECG and pregnancy assessment, before prescribing.
  3. 3Start the product-specific regimen under specialist oversight, document shared-care responsibilities and schedule the first correctly timed level at one week.
02Stable monitoringUse level and organ calendarsThe lithium dose and plasma concentration are stable without current toxicity or relapse concern.+
  1. 1Check the plasma level every three months during year one and thereafter at the six- or three-month interval determined by individual risk.

Regimens, contraindications and interactions

A product-specific example of lithium used for bipolar treatment and prophylaxis within specialist initiation and shared-care monitoring.

Priadel prolonged-release lithium carbonate

The product regimen is individualised; an average-weight adult may start 400 to 1200 mg by mouth daily as one or two doses, with a plasma level four to seven days later and subsequent dose adjustment to the agreed target.

Do not crush prolonged-release tablets or switch brands casually; severe renal insufficiency, dehydration, low sodium, pregnancy, interacting NSAIDs or renin-angiotensin medicines and inability to monitor require specialist review.

Complications, monitoring and follow-up

  • Measure plasma lithium one week after initiation and every dose change and weekly until stable; document formulation, dose time and sample time.
  • Check plasma concentration every three months in year one, then every six months or every three months when NICE high-risk criteria apply.
  • Measure weight or BMI, eGFR, urea and electrolytes, calcium and thyroid function every six months, with increased frequency for abnormal trends or symptoms.
  • At every appointment ask about tremor, paraesthesia, gait, cognition, gastrointestinal loss, fluid and salt change, adherence, pregnancy and interacting medicines.
  • If stopping, taper for at least four weeks and preferably up to three months and monitor closely for mania and depression during the reduction and for three months afterward.

Special situations

The sample has a history

A lithium concentration is uninterpretable without the exact last dose time, blood time, formulation, adherence and recent fluid or renal change.

Symptoms outrank reassurance

Neurological toxicity can occur within a reported therapeutic range, so a normal-looking number must not override a concerning examination.

Brand change is clinical

Different lithium preparations have different bioavailability; changing product requires the caution and monitoring used for a new initiation.

Renal trends matter

Two or more falling eGFR results require rate assessment and more frequent monitoring, with renal and psychiatric expertise when continuation is uncertain.

Sick-day advice prevents harm

The patient needs an actionable plan for vomiting, diarrhoea, fever and poor intake before illness occurs, not only after toxicity develops.

Common pitfalls

  1. 01

    Starting lithium before baseline renal, thyroid, calcium, blood-count and monitoring responsibilities are complete.

  2. 02

    Interpreting a random plasma concentration without recording the product and timing of the last dose and sample.

  3. 03

    Reassuring a neurologically symptomatic patient because the lithium result lies inside the laboratory therapeutic range.

  4. 04

    Allowing over-the-counter NSAID use or starting an interacting prescription without a level and monitoring plan.

  5. 05

    Using six-monthly levels after year one for an older patient or someone with a level at or above 0.8 mmol/L.

  6. 06

    Switching lithium brands as though the formulations were automatically bioequivalent.

  7. 07

    Stopping suddenly after stable long-term treatment and overlooking the increased relapse risk.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
PsychiatryOriginal SBA

First level timing

A patient starts lithium for the first time after baseline tests and shared-care arrangements are complete. When should the first plasma lithium level usually be measured according to NICE?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Psychiatry topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE CG185 bipolar disorder recommendationsLithium initiation, target ranges, ongoing monitoring, interactions and discontinuation.
  • NHS Specialist Pharmacy Service lithium monitoringProfessional baseline, sampling, ongoing monitoring and toxicity-action summary.
  • Priadel tablets summary of product characteristicsProduct-specific dosing, plasma sampling, contraindications, toxicity and preparation advice.
  • NHS lithium side effectsPatient-facing recognition of serious adverse effects and emergency action.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Dose is individualised to response and plasma concentration. NICE advises measuring one week after starting, one week after every change and weekly until stable. For first-time prescribing, aim for 0.6 to 0.8 mmol/L. A six-month trial at 0.8 to 1.0 mmol/L may be considered after relapse on lithium or when subthreshold symptoms cause functional impairment. Use a consistently timed trough sample according to local and product instructions, commonly twelve hours after the last dose, and record the time of dose and blood draw.

Ongoing monitoring has two tempos. Plasma levels are checked every three months during year one; after that, every six months for lower-risk stable patients and every three months for older people, interacting drugs, organ-risk states, poor symptom control, poor adherence or a last level of 0.8 mmol/L or higher. Weight or BMI, eGFR, urea and electrolytes, calcium and thyroid function are checked every six months, sooner if clinical change or serial renal decline occurs.

Toxicity can occur despite a concentration reported within the therapeutic range, especially in chronic exposure or a vulnerable patient. Ask at every appointment about paraesthesia, tremor, gait, cognition, gastrointestinal symptoms and fluid change. Diarrhoea, vomiting, fever, sweating, dietary sodium change, acute kidney injury and interacting medicines can raise exposure. When toxicity is suspected, withhold lithium and arrange emergency clinical, biochemical and cardiac assessment; a delayed level must never postpone supportive treatment or toxicology advice.

Key points

  • Required baseline includes weight or BMI, full blood count, urea and electrolytes including calcium, eGFR and thyroid function; add ECG for cardiovascular disease or risk and assess pregnancy where relevant.
  • Do not initiate lithium without facilities for regular plasma levels, organ monitoring, safety information and an explicit specialist-primary-care shared-care arrangement.
  • First plasma level is measured one week after starting and one week after every dose change, then weekly until stable using the locally specified post-dose sampling time.
  • For a person prescribed lithium for the first time, NICE usually targets 0.6 to 0.8 mmol/L; consider 0.8 to 1.0 mmol/L for at least six months only in specified relapse or residual-symptom circumstances.
  • Measure levels every three months during the first year, then every six months, or every three months in older people and others with interaction, organ, adherence, symptom or higher-level risk.
  • Check weight or BMI, eGFR, urea and electrolytes, calcium and thyroid function every six months, increasing frequency when results change or symptoms suggest organ effects.
  • Teach stable fluid and salt intake, action during vomiting, diarrhoea or acute illness, avoidance of over-the-counter NSAIDs and prompt reporting of pregnancy or toxicity symptoms.
  • Toxicity is a clinical diagnosis supported by a level: withhold lithium and obtain urgent level and renal-electrolyte assessment whenever symptoms are concerning, even within the therapeutic range.
  • If lithium is stopped, reduce over at least four weeks and preferably up to three months, with close relapse monitoring during reduction and for three months afterward.
  • Syncope, bradycardia, arrhythmia, severe hypotension or collapse during lithium treatment requires urgent ECG, electrolyte and medical evaluation.
  • Pregnancy, planned pregnancy or significant decline in eGFR changes the benefit-harm balance and requires coordinated specialist review rather than abrupt stopping.
    • 05
    Urgent toxicity work-up
    Why
    Assess concentration, renal and electrolyte disturbance, cardiac effects, co-exposures and physiological severity.
    Interpretation and limitations
    Clinical features determine urgency. Repeat levels and enhanced elimination decisions follow toxicology advice because absorption and tissue redistribution vary.
  • 2Measure renal function, electrolytes, calcium, thyroid function and weight or BMI at least every six months and act on trends.
  • 3At every contact review symptoms, sick-day events, hydration, salt change, pregnancy intentions, adherence and newly prescribed or over-the-counter interactions.
    • 03Suspected toxicityWithhold and assess urgentlyA lithium-treated patient develops compatible gastrointestinal, neurological, renal or cardiac symptoms or a concerning exposure change.+
    1. 1Stop further lithium doses, assess ABCDE, fluid state, neurological signs, last dose, formulation, co-ingestants and recent illness or interacting drugs.
    2. 2Obtain urgent lithium concentration, renal-electrolyte tests and ECG and contact emergency medicine and toxicology according to clinical severity.
    3. 3Trend symptoms and levels, treat complications and restart only after the cause, renal recovery, target and monitoring schedule are safely resolved.